Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.
Aparna R ParikhAmirkasra MojtahedJaime L SchneiderKatie KanterEmily E Van SeventerIsobel J FetterAshraf ThabetMadeleine G FishBezaye TeshomeKathryn FosbennerBrandon A NadresHeather A ShahzadeJill N AllenLawrence S BlaszkowskyDavid P RyanBruce GiantonioLipika GoyalRyan D NippEric J RoelandColin D WeekesJennifer Y WoAndrew X ZhuDora Dias-SantagataA John IafrateJochen K LennerzTheodore S HongGiulia SiravegnaNora HorickJeffrey W ClarkRyan B CorcoranPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Serial ctDNA monitoring may provide early indication of response to systemic therapy in patients with metastatic gastrointestinal cancer prior to radiographic assessments and may outperform standard tumor markers, warranting further evaluation.